(S)-3-氨基-3-(2-甲基苯基)-丙酸 | 736131-48-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-3-氨基-3-(2-甲基苯基)-丙酸
• 中文别名: (S)-3-氨基-3-(2-甲基苯基)丙酸
• 英文名称: (S)-3-amino-3-(2-methylphenyl)propionic acid
• 英文别名: (S)-3-amino-3-(o-tolyl)propanoic acid；methyl-β-phenylalanine；(S)-3-amino-3-o-tolylpropionic acid；(S)-3-amino-3-(2-methyl-phenyl)-propionic acid；(S)-3-amino-3-(2-methyl-phenyl)propionic acid；(S)-3-amino-3-o-tolyl-propionic acid；(3S)-3-amino-3-(2-methylphenyl)propanoic acid
• CAS: 736131-48-9
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD04113679
• 分子量: 179.219
• InChiKey: GORGZFRGYDIRJA-VIFPVBQESA-N

物化性质

• 沸点：
  326.3±30.0 °C(Predicted)
• 密度：
  1.163±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(S)-3-Amino-3-(2-methyl-phenyl)-propionic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(S)-3-Amino-3-(2-methyl-phenyl)-propionic acid
Ingredient name:
CAS number: 736131-48-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H13NO2
Molecular weight: 179.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

(S)-3-氨基-3-(2-甲基苯基)丙酸是一种β-氨基丙酸的手性衍生物，可用作医药中间体。

该化合物可通过化学合成方法制备。其中，氨基丙酸部分可以由四元杂环内酰胺的分子内开环反应生成，也可以通过苯乙烯加成反应获得。

反应信息

• 作为反应物：
  描述：

  (S)-3-氨基-3-(2-甲基苯基)-丙酸 在 N,N-二甲基甲酰胺 氯化亚砜 、 草酰氯 、 水 、 三乙胺 、 sodium hydroxide 作用下， 以 2-甲基四氢呋喃 、 二氯甲烷 为溶剂， 反应 54.0h， 生成 (S)-3-{[1-(2-fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-(2-methyl-phenyl)-propionic acid amide
  参考文献：
  名称：

  [EN] OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  [FR] DÉRIVÉS D'ACIDE 3-HÉTÉROAROYLAMINO-PROPIONIQUE À SUBSTITUTION OXYGÈNE ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES

  摘要：

  本发明涉及公式I的化合物，其中A、D、E、G、R10、R30、R40、R50和R60具有索引声明中指示的含义，这些化合物是有价值的药用活性化合物。它们是蛋白酶卡特普辛A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及公式I化合物的制备方法、它们的用途以及包含它们的药物组合物。

  公开号：

  WO2011092187A1
• 作为产物：
  描述：

  4-(邻甲苯基)氮杂环丁烷-2-酮 在 盐酸 、 水 作用下， 以 甲基叔丁基醚 为溶剂， 反应 9.0h， 生成 (S)-3-氨基-3-(2-甲基苯基)-丙酸
  参考文献：
  名称：

  Enzymatic preparation of (S)-3-amino-3-(o-tolyl)propanoic acid, a key intermediate for the construction of Cathepsin inhibitors

  摘要：

  Enantiomerically pure (S)-3-amino-3-(o-tolyl)propanoic acid [(S)-6], identified as the preferred enantiomeric form for the construction of novel beta-amino acid derivatives as inhibitors of Cathepsin, was prepared through both indirect and direct enzymatic strategies. Resolution of hydroxymethylated beta-lactam (+/-)-1 through Burkholderia cepacia lipase PSIM-catalysed R-selective butyrylation (E > 200) was first carried out in t-BuOMe. Treatment of the unreacted (S)-1 with 18% HCl then furnished the desired (S)-6 center dot HCl. Next, Candida antarctica lipase B catalysed the ring cleavage of racemic 4-(o-tolyl)azetidin-2-one [(+/-)-2] with excellent R enantioselectivity (E > 200), either in t-BuOMe with added H2O as nucleophile or in H2O at 60 degrees C. Hydrolysis of the less reactive beta-lactam enantiomer [(S)-2] with 18% HCl afforded (S)-6 center dot HCl. A direct enzymatic route to enantiomeric (S)-6 was finally optimized through the lipase PSIM-catalysed S-enantioselective (E>200) hydrolysis of racemic ethyl 3-amino-3-(o-tolyl)propanoate [(+/-)-3] in t-BuOMe with added H2O at 45 degrees C or in H2O at 3 degrees C. (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molcatb.2013.04.001

文献信息

• [EN] 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS<br/>[FR] COMPOSÉS 4-HYDROXY-ISOQUINOLÉINE COMME INHIBITEURS D'HYDROXYLASE HIF
  申请人：FIBROGEN INC

  公开号：WO2013134660A1

  公开（公告）日：2013-09-12

  The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

  本发明涉及式(I)的新化合物，以及能够选择性地抑制PHD1酶活性而不影响其他同工酶（例如PHD2和/或PHD3酶）的组合物。该发明还涉及式(I)的化合物在肌肉退化、结肠炎、炎症性肠病和某些缺血症等疾病中的应用。
• The Bacterial Ammonia Lyase EncP: A Tunable Biocatalyst for the Synthesis of Unnatural Amino Acids
  作者：Nicholas J. Weise、Fabio Parmeggiani、Syed T. Ahmed、Nicholas J. Turner

  DOI：10.1021/jacs.5b07326

  日期：2015.10.14

  deracemization cascades (giving (S)- or (R)-α-phenylalanine derivatives, respectively), and also eukaryotic phenylalanine aminomutases (PAMs) for the synthesis of the (R)-β-products. Herein, we present the investigation of another family member, EncP from Streptomyces maritimus, thereby expanding the biocatalytic toolbox and enabling the production of the missing (S)-β-isomer. EncP was found to convert

  I类裂解酶家族的酶催化氨向丙烯酸芳基酯的不对称加成，产生作为产物的高价值氨基酸。最近的例子包括使用苯丙氨酸氨裂解酶 (PAL)，单独使用或作为去消旋级联的途径（分别提供 (S)- 或 (R)-α-苯丙氨酸衍生物），以及真核苯丙氨酸氨基变位酶 (PAM) (R)-β-产物的合成。在此，我们介绍了对来自 Streptomyces maritimus 的另一个家族成员 EncP 的研究，从而扩展了生物催化工具箱并能够生产缺失的 (S)-β-异构体。发现 EncP 将一系列芳基丙烯酸酯转化为 (S)-α- 和 (S)-β-芳基丙氨酸的混合物，其区域选择性与每个底物环上的吸电子/供电子基团的强度相关。野生型酶的低区域选择性通过基于结构的合理设计得到解决，以产生三种对α-或β-产物具有改变偏好的变体。通过检查各种生物催化剂/底物组合，证明可以调整反应的胺化模式，以根据需要实现 99:1 和 1:99 之间的
• [EN] AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS DE L'ACIDE 3-HÉTÉROAROYLAMINO-PROPIONIQUE AMINO SUBSTITUÉS ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2012101199A1

  公开（公告）日：2012-08-02

  Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals The present invention relates to compounds of the formula (I), wherein A, D, E, G, R10 R11, R30 R40 R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  氨基取代的3-杂环酰胺基丙酸衍生物及其作为药物的用途。本发明涉及式(I)的化合物，其中A、D、E、G、R10、R11、R30、R40、R50和R60具有权利要求中所示的含义，它们是有价值的药用活性化合物。它们是蛋白酶卡特普西A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备式I化合物的方法、它们的用途以及包含它们的药物组合物。
• AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：RUF Sven

  公开号：US20120232112A1

  公开（公告）日：2012-09-13

  The present invention relates to compounds of the formula I, wherein A, D, E, G, R 10 , R 11 , R 30 , R 40 , R 50 and R 60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的化合物， 其中A、D、E、G、R10、R11、R30、R40、R50和R60 具有权利要求中所示的含义，它们是有价值的药用活性化合物。它们是蛋白酶卡特普辛A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备式I化合物的方法，它们的用途以及包含它们的药物组合物。
• Novel β-Amino Acid Derivatives as Inhibitors of Cathepsin A
  作者：Sven Ruf、Christian Buning、Herman Schreuder、Georg Horstick、Wolfgang Linz、Thomas Olpp、Josef Pernerstorfer、Katrin Hiss、Katja Kroll、Aimo Kannt、Markus Kohlmann、Dominik Linz、Thomas Hübschle、Hartmut Rütten、Klaus Wirth、Thorsten Schmidt、Thorsten Sadowski

  DOI：10.1021/jm300663n

  日期：2012.9.13

  molecule inhibitors of CatA with oral bioavailability have been described to allow further pharmacological profiling. In our work we identified novel β-amino acid derivatives as inhibitors of CatA after a HTS analysis based on a project adapted fragment approach. The new inhibitors showed beneficial ADME and pharmacokinetic profiles, and their binding modes were established by X-ray crystallography. Further

  组织蛋白酶A（CatA）是分布在溶酶体，细胞膜和细胞外空间之间的丝氨酸羧肽酶。包括缓激肽和血管紧张素I在内的几种肽激素已被描述为底物。因此，抑制CatA在心血管疾病中具有有益作用的潜力。天然产物依贝内酯B对CatA的药理抑制作用可增加肾缓激肽水平，并防止盐诱导的高血压的发展。但是，到目前为止，尚未描述具有口服生物利用度的CatA小分子抑制剂可进行进一步的药理分析。在我们的工作中，基于基于项目的片段方法对HTS进行分析后，我们确定了新型β-氨基酸衍生物作为CatA抑制剂。新的抑制剂表现出有益的ADME和药代动力学特性，通过X射线晶体学建立了它们的结合方式。进一步的研究导致了迄今未知的CatA在心脏肥大中的病理生理作用。我们的一种抑制剂目前正在进行I期临床试验。